Estradiol valerate/dienogest

Drug Profile

Estradiol valerate/dienogest

Alternative Names: Climodien; Climodiène; Dienogest/estradiol valerate; DNG/E2V; E2V/DNG; Klimodien; Lafamme

Latest Information Update: 05 Feb 2015

Price : $50

At a glance

  • Originator Jenapharm
  • Class Estradiol congeners; Estrenes; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis
  • Discontinued Contraception

Most Recent Events

  • 05 Feb 2015 Launched for Postmenopausal osteoporosis in Turkey (PO) before February 2015
  • 05 Feb 2015 Launched for Menopausal syndrome in France, Belgium, Greece, Portugal, the Czech Republic, Spain, Russia and Turkey (PO) before February 2015
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top